AbbVie Inc.

AbbVie Inc.

5,486.00
MXN
-27.00
(-0.49%)
105.40EPS
45.19P/E
8.44TMarket Cap
Feb 03Next Earn

Total Valuation

MXN

As of September 30, 2026, AbbVie, Inc. carries a market capitalization of 8.44T, placing it among publicly traded companies globally. Its enterprise value stands at 9.71T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.44T
Enterprise Value9.71T

Important Dates

AbbVie, Inc.'s next confirmed earnings release is scheduled for February 3, 2027.

Earnings Date2/3/2027

Share Statistics

As of September 30, 2026, AbbVie, Inc. has 1.77B shares outstanding.

Shares Outstanding1.77B

Valuation Ratios

As of September 30, 2026, AbbVie, Inc. trades at a trailing price-to-earnings ratio of 45.19. The price-to-sales ratio is 7.08, and the price-to-book ratio stands at -101.99.

PE Ratio45.19
PS Ratio7.08
PB Ratio-101.99
P/TBV Ratio-4.72
P/FCF Ratio24.84
P/OCF Ratio23.26

Enterprise Valuation

As of September 30, 2026, AbbVie, Inc. trades at an EV/EBITDA multiple of 18.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.32 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. AbbVie, Inc. trades at an EV/FCF ratio of 25.26, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 9.71T versus a market cap of 8.44T, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.14
EV / EBITDA18.60
EV / EBIT25.32
EV / FCF25.26

Financial Position

As of September 30, 2026, AbbVie, Inc. maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,782.79, indicating conservative leverage, while an interest coverage ratio of 9.70 demonstrates adequate ability to service its debt obligations.

Current Ratio0.87
Quick Ratio0.56
Debt / Equity-1,782.79
Debt / EBITDA2.80
Interest Coverage9.70

Financial Efficiency

MXN

These figures cover the twelve months ended September 30, 2026. Return on invested capital (ROIC) comes in at 24.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.88, useful for judging operating efficiency across full business cycles. The company generates approximately 20.91M in revenue per employee across its workforce of 57,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.39 indicates how many times AbbVie, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)7.35
Return on Invested Capital (ROIC)24.06
Return on Capital Employed (ROCE)17.88
Revenue Per Employee20.91M
Employee Count57,000.00
Inventory Turnover3.39

Taxes

MXN

Over the twelve months ended September 30, 2026, AbbVie, Inc. recorded 44.53B in income tax expense. That works out to an effective tax rate of 19.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 231.38B, leaving 186.75B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax44.53B
Effective Tax Rate19.24

Stock Price Statistics

MXN

As of the close on November 13, 2026, AbbVie, Inc.'s stock has gained approximately 27.78% over the past 52 weeks. The 50-day moving average sits at 4,969.46, while the 200-day moving average is 4,222.10.

52-Week Price Change27.78%
50-Day Moving Average4,969.46
200-Day Moving Average4,222.10

Income Statement

MXN

Over the twelve months ended September 30, 2026, AbbVie, Inc. generated 1.19T in revenue and converted that into 186.75B in net income, yielding earnings per share of 105.40. EBITDA reached 521.85B, while operating income came in at 428.84B.

Revenue1.19T
Gross Profit878.80B
Operating Income428.84B
Pretax Income231.38B
Net Income186.75B
EBITDA521.85B
EBIT383.41B
Earnings Per Share (EPS)105.40

Balance Sheet

MXN

As of September 30, 2026, AbbVie, Inc. holds 194.55B in cash and equivalents against 1.46T in total debt, resulting in a net debt position of 1.27T. Total book value stands at -82.76B, with working capital of -101.52B providing operational flexibility.

Cash & Cash Equivalents194.55B
Total Debt1.46T
Net Debt1.27T
Equity (Book Value)-82.76B
Book Value Per Share-46.82
Working Capital-101.52B

Cash Flow

MXN

AbbVie, Inc. produced 362.75B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -21.98B in capital expenditures, free cash flow totaled 340.77B - equivalent to 192.82 per share.

Operating Cash Flow362.75B
Capital Expenditures-21.98B
Free Cash Flow340.77B
FCF Per Share192.82

Margins

Over the twelve months ended September 30, 2026, AbbVie, Inc. posted a gross margin of 73.72, reflecting its pricing power and cost economics. The operating margin of 35.98 and net profit margin of 15.67 provide insight into operational efficiency.

Gross Margin73.72
Operating Margin35.98
Pretax Margin19.41
Profit Margin15.67
EBITDA Margin43.78

Dividends & Yields

MXN

Over the twelve months ended September 30, 2026, AbbVie, Inc. paid dividends of 124.02 per share. The dividend payout ratio of 117.23 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AbbVie, Inc. shareholders.

Dividend Per Share124.02
Payout Ratio117.23
Shareholder Yield0.32
FCF Yield4.03

Scores

As of September 30, 2026, AbbVie, Inc. has an Altman Z-Score of 4.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.00